RASGRF1 and neuroblastoma: Toward this end, we choose three different human neuronal model systems to evaluate efficacy of three different BAM compounds for their capability to promote RasGRF1‐dependent increases in dendritic spine density: undifferentiated SH‐SY5Y neuroblastoma cells, retinoic acid (RA)‐induced differentiated SH‐SY5Y neuroblastoma cells, and mature neurons derived from human‐induced pluripotent stem cells (iPSCs).